Financials in USD. Standardized financial statements.
A compact view of how Mirati Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $12.44M | $72.09M | $13.40M | $3.33M | $12.93M | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | -82.7% | +438.1% | +301.7% | -74.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $600,000 | $1.78M | $299.35M | $182.87M | $93.87M | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $11.84M | -$436.50M | -$285.95M | -$179.53M | -$80.95M | -$58.09M | -$68.49M | $0 | $0 | $0 |
| Gross Margin? | +95.2% | -605.5% | -2134.3% | -5383.2% | -626.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $771.42M | $645.27M | $382.76M | $33.73M | $115.55M | $71.53M | $83.78M | $64.71M | $38.77M | $31.97M |
| Operating Income? | -$759.59M | -$573.18M | -$369.36M | -$222.10M | -$102.63M | -$71.53M | -$83.78M | -$64.71M | -$38.77M | -$30.97M |
| EBITDA? | -$756.66M | -$571.40M | -$368.72M | -$221.85M | -$102.63M | -$71.53M | -$83.78M | -$64.71M | $2.01M | -$31.97M |
| Income Before Tax | -$740.36M | -$578.49M | -$357.94M | -$213.26M | -$98.42M | -$70.43M | -$83.12M | -$64.54M | -$43.70M | -$52.88M |
| Income Tax Expense | $508,000 | $3.30M | -$511,000 | -$659,000 | $0 | -$130,000 | -$155,000 | -$249,000 | $121,000 | -$23,000 |
| Net Income? | -$740.87M | -$581.78M | -$357.94M | -$213.26M | -$98.42M | -$70.43M | -$83.12M | -$64.54M | -$43.68M | -$52.87M |
| EPS? | $-13.18 | $-11.21 | $-7.96 | $-5.69 | $-3.19 | $-2.79 | $-4.20 | $-3.82 | $-3.24 | $-4.78 |
| Diluted EPS? | $-13.18 | $-11.21 | $-7.96 | $-5.69 | $-3.19 | $-2.79 | $-4.20 | $-3.82 | $-3.24 | $-4.78 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality